Karuna Therapeutics is a technology company.
Karuna Therapeutics has raised $110.0M across 2 funding rounds.
Key people at Karuna Therapeutics.
Karuna Therapeutics has raised $110.0M in total across 2 funding rounds.
Karuna Therapeutics has raised $110.0M in total across 2 funding rounds.
Karuna Therapeutics's investors include Amino Capital, ARCH Venture Partners, Dolby Family Ventures, Ed Mathers, Sofinnova Investments, SR One, Bill Gates, Sue Xu, Third Rock Ventures.
Karuna Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, particularly psychiatric and neurological conditions such as schizophrenia and dementia-related psychosis. Its lead product candidate, KarXT, targets muscarinic receptors in the brain to reduce psychotic symptoms and improve cognition, aiming to offer a more holistic and better-tolerated treatment option than existing therapies. The company serves patients with severe neuropsychiatric disorders, addressing the significant unmet need for effective and safer treatments, and has demonstrated promising clinical results that support its growth momentum and pipeline expansion[1][2][3].
Founded by experts in neuroscience and drug development, Karuna emerged from research into muscarinic receptor agonists originally intended for Alzheimer's disease memory impairment, which serendipitously showed efficacy in reducing psychosis symptoms. The company innovated by combining xanomeline with trospium to block side effects that had previously halted development, enabling advancement into clinical trials. This breakthrough and subsequent collaborations, such as with PsychoGenics for drug discovery, have been pivotal in establishing Karuna’s position in CNS drug development[1][3][7].
Karuna is riding the trend of precision neuroscience therapeutics, addressing the complexity of CNS disorders with targeted receptor modulation rather than broad-spectrum antipsychotics. The timing is critical as the global burden of neuropsychiatric diseases grows and existing treatments often have limited efficacy and significant side effects. Advances in molecular biology, receptor pharmacology, and computational drug discovery create favorable market forces for Karuna’s approach. By advancing first-in-class therapies, Karuna influences the broader ecosystem by setting new standards for safety and efficacy in psychiatric treatment and inspiring innovation in CNS drug development[1][2][3].
Now a wholly owned subsidiary of Bristol Myers Squibb as of 2024, Karuna is positioned to accelerate the commercialization of KarXT, with a Prescription Drug User Fee Act (PDUFA) date set for September 26, 2024, for schizophrenia treatment. Future trends shaping their journey include expanding indications (e.g., Alzheimer’s psychosis, Bipolar I disorder), leveraging machine learning for drug discovery, and integrating into a larger biopharma infrastructure to scale impact. Karuna’s influence is likely to grow as it helps redefine treatment paradigms for CNS disorders, potentially transforming patient outcomes and setting a precedent for innovative neuroscience therapeutics[8].
Key people at Karuna Therapeutics.
Karuna Therapeutics has raised $110.0M across 2 funding rounds. Most recently, it raised $68.0M Series B in March 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2019 | $68.0M Series B | Amino Capital, ARCH Venture Partners, Dolby Family Ventures, Ed Mathers, Sofinnova Investments, SR One, Bill Gates, Sue Xu | |
| Aug 1, 2018 | $42.0M Series A | Amino Capital, ARCH Venture Partners, Third Rock Ventures, Bill Gates, Sue Xu |
